Skip to content
HowShorted

CORCEPT THERAPEUTICS INC short interest in 2022

In 2022, CORCEPT THERAPEUTICS INC's disclosed short interest ran from 16.62% of shares outstanding on 14 Jan 2022 to 13.01% on 30 Dec 2022, a change of -3.61 percentage points. The year's high was 19.11% on 13 May 2022 and its low 12.40% on 15 Dec 2022, averaging 15.96% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 41.25 days on 30 Nov 2022. Full history: CORCEPT THERAPEUTICS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for CORCEPT THERAPEUTICS INC in 2022

2022 in figures

Start of year
16.62% (14 Jan 2022)
End of year
13.01% (30 Dec 2022)
Change
-3.61 pp
High
19.11% (13 May 2022)
Low
12.40% (15 Dec 2022)
Average
15.96%
Highest days to cover
41.25 (30 Nov 2022)
SEC filings marked
8

Every report in 2022

CORCEPT THERAPEUTICS INC short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 202216.62%23.33
31 Jan 202215.76%21.62
15 Feb 202215.42%19.6210-K filed, results (8-K)
28 Feb 202215.29%16.65
15 Mar 202215.63%18.36
31 Mar 202215.20%15.32
14 Apr 202215.63%17.69
29 Apr 202217.06%18.50
13 May 202219.11%17.1210-Q filed, results (8-K)
31 May 202218.11%24.55
15 Jun 202217.10%26.85
30 Jun 202216.99%23.13
15 Jul 202216.69%21.82
29 Jul 202216.74%30.71
15 Aug 202216.37%26.12results (8-K), 10-Q filed
31 Aug 202216.20%33.83
15 Sep 202215.94%34.24
30 Sep 202216.18%27.92
14 Oct 202216.05%38.35
31 Oct 202215.84%34.18
15 Nov 202215.17%20.0410-Q filed, results (8-K)
30 Nov 202214.48%41.25
15 Dec 202212.40%11.54
30 Dec 202213.01%16.54

See also: CORCEPT THERAPEUTICS INC's full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.